Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study

The central role of the propensity score in observational studies for causal effects

Paul R. Rosenbaum, Donald B. Rubin · Biometrika · 1983 · 31K citations · Full text

Public Health, Biostatistics, Causal Inference +16

Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data

Hude Quan, Vijaya Sundararajan, Patricia Halfon et al. · Medical Care · 2005 · 10.6K citations

Health Professions, Internal Medicine, Clinical Classification Systems +16

Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual

Jeffrey E. Gershenwald, Richard A. Scolyer, Kenneth R. Hess et al. · CA A Cancer Journal for Clinicians · 2017 · 2.3K citations · Full text

Medicine, Oncology, Surgery +17

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio et al. · New England Journal of Medicine · 2017 · 2.2K citations · Full text

Life Sciences, Oncology, Pharmacotherapy +17

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà et al. · New England Journal of Medicine · 2018 · 1.9K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17